Viragen, Inc.

In vitro study results show anti-viral activity of multiferon against bird flu virus

Published in Medicine and Law Weekly, December 30th, 2005

Viragen, Inc. (VRA) and Viragen International, Inc. (VGNI) announced that preliminary in vitro studies conducted by a U.S. research organization have found Multiferon to show significant anti-viral activity against the highly pathogenic H5N1 strain of avian influenza virus.

These early-stage studies found Multiferon (multi-subtype, human natural alpha interferon) to be significantly more active against the virus than recombinant alpha interferon, recombinant beta interferon or ribavirin. Viragen officials believe these results suggest that Multiferon may have utility against this viral threat and is a prime candidate worthy of further evaluation in additional avian...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-12-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry